Genmab — Februar 2025
-
at least GEN3017 did not cost too much; they had only recruited 9 patients when they stopped it https://clinicaltrials.gov/study/NCT06018129?tab=history&a=20&b=21#version-content-panel
-
Genmab angriber modstandslinje ved kurs 1600 https://proinvestor.com/investornyt/1282884/genmab-angriber-modstandslinje-ved-kurs-1600
-
I am not really seeing anything at 1600, but we have now broken above the down-trend line from the ATH in Dec22. We haven't been able to break above the 1630-1650ish area since September, so it would be nice if we can to that. We now rallied 332dkk from the last bottom, last time we managed that was February last year when we rallied 346dkk up from 1825 to 2171
-
Det med knappenålen er ikke til at sige. Tilbage i september var processen uklart. I november hed det pludselig 60 dage og binær beslutning. Så blev det usikkert, om de 60 dage startede lige før eller efter nytår. Og så blev det i januar til senest i 1. kvartal (og hypotetisk set med ny forhandling ind over). Egentlig lidt uskønt synes jeg.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind
